|This Slide: #40 of 83|
Slide #40. StemCells, Inc. — Seminal Neural Stem Cell Patent Portfolio
StemCells, Inc. (STEM)
Seminal Neural Stem Cell Patent Portfolio
StemCells, Inc. (Nasdaq:STEM) today announced the acquisition of a portfolio of issued US and Canadian patents to which it had previously held an exclusive worldwide license. The portfolio broadly claims the manufacture and proliferation of purified populations of human neural stem cells and their use as therapeutics and as tools for drug discovery. The acquisition relieves the Company of all milestone and royalty obligations under the license agreements for products claimed by the patents, such as products derived from the Company's proprietary HuCNS-SC cells (purified human neural stem cells). The patents arose from the groundbreaking research of Samuel Weiss, Ph.D., and Brent Reynolds, Ph.D., while at the University of Calgary. As consideration for the portfolio, the Company will issue 139,548 shares of common stock to Neurospheres Holdings Ltd., an intellectual property holding company affiliated with the University of Calgary.
StemCells is engaged in the research, development, and commercialization of stem cell therapeutics. Co. is focused on developing and commercializing stem and progenitor cells as the basis for new therapeutics and therapies, as well as focused on identifying and developing stem and progenitor cells as potential therapeutic agents. Co.'s lead product development program is its CNS (central nervous system) Program, in which it is developing applications for HuCNS-SC® cells, its proprietary human neural platform technology. Co. also in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system, which includes the brain, spinal cord and eye.
Open the STEM Page at The Online Investor »
Hold (2.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite